CignaLow ImpactCoverage
A personalized approach, biologic utilization, and new management strategies for treating severe asthma
Published June 2, 2026
AI Summary
Cigna Healthcare has published comprehensive coverage policies for seven FDA-approved biologic therapies for treating severe asthma, including the newly approved EXDENSUR. This is an informational update outlining available biologics and their coverage policies rather than announcing specific billing changes.
Action Required
Review linked Cigna Healthcare coverage policies for XOLAIR, NUCALA, FASENRA, DUPIXENT, TEZSPIRE, and CINQAIR to understand current prior authorization and coverage requirements for biologic asthma treatments. Consider Accredo Specialty Pharmacy for eligible patients.
Plan Types
Commercial
Specialties
pulmonology, allergy-immunology, internal-medicine, family-medicine, pediatrics